SCHEMBL3016465

SCHEMBL3016465

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(OC)ccc4OC)CC3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2997817 0.94 ALDH1A1 (0.47) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3011144 0.93 MAPT (0.37) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3008084 0.93 ALDH1A1 (0.43) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3017048 0.93 LMNA (0.44) ALDH1A1HPGDHSD17B10SMN1; SMN2LMNA
SCHEMBL3017874 0.93 LMNA (0.36) ALDH1A1HPGDHSD17B10SMN1; SMN2LMNA
SCHEMBL3016470 0.92 ALDH1A1 (0.42) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3004114 0.91 ALDH1A1 (0.43) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3012043 0.91 ALDH1A1 (0.42) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3003017 0.91 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL3007686 0.91 KMT2A (0.45) ALDH1A1HPGDHSD17B10SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885HPGD 2894/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.